AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02245477 — intervention group
Intervention type: DEVICE
Intervention: obstetric Ultrasound
Description: Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
Study NCT02245477 — intervention group
Intervention type: OTHER
Intervention: serum Vascular Endothelial Growth Factor
Description: Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
Study NCT03215017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Description: Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
Study NCT02436473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1150ppm F
Description: US marketed toothpaste containing 1150ppm of F
Study NCT02436473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste containing 0ppm F
Description: Experimental toothpaste containing 0ppm F
Study NCT02436473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 250ppm F
Description: Experimental toothpaste containing 250ppm F
Study NCT02436473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 1150ppm F
Description: Experimental toothpaste containing 1150ppm F
Study NCT01263665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25 cm GORE® VIABAHN®
Description: 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
Study NCT03215017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
Study NCT05112575 — intervention group
Intervention type: RADIATION
Intervention: Postoperative imaging with magnetic resonance imaging or computed tomography
Description: Postoperative imaging control with magnetic resonance or computed tomography after craniotomy for vascular or neurooncological operations.
Study NCT04386200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based thecnologies
Description: Integration of traditional face-to-face educational approach with web-based technologies.
Study NCT04386200 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: traditional approach
Description: traditional face-to-face educational approach
Study NCT02823769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SI-R21204 resin composite
Description: Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
Study NCT02823769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanohybrid resin composite
Description: One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
Study NCT01336933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01336933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01336933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given PO or IV
Study NCT01336933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT01336933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatrexate
Description: Given IV
Study NCT01336933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: comparative genomic hybridization
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: nucleic acid sequencing
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study NCT01336933 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT03767621 — intervention group
Intervention type: OTHER
Intervention: Indication of revascularization
Description: Device: iFR/FFR
Study NCT03839368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of angle fracture
Description: open reduction and internal fixation of angle fracture
Study NCT03839368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixation of angle fracture
Description: open reduction and internal fixation of angle fracture
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin or epirubicin
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin or epirubicin
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin or epirubicin
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT02641847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02316730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanchi-Tongshu Capsule (Enteric coated pellets)
Description: Take 0.7g (2 Capsules) of test preparation orally.
Study NCT02316730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sanchi-Tongshu Capsule
Description: Take 0.4g (2 Capsules) of reference preparation orally.
Study NCT03034486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D930, D565
Description: Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
Study NCT02611973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspirin therapy interruption
Description: Stop the treatment by aspirin 100mg/d in the experimental arm.
Study NCT02611973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment by aspirin 100 mg/d in the active comparator arm
Description: HU+ aspirin maintenance
Study NCT02611973 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No interruption of aspirin in the Observational arm
Description: patient with Contre indication to aspirin or required antithrombotic therapy
Study NCT02611973 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance
Study NCT02611973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance
Study NCT02611973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment (HU)
Description: HU maintenance
Study NCT00525512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium 18 mcg
Description: Oral inhalation once daily of 18mcg tiotropium via handihaler
Study NCT00525512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation of once-daily placebo matching tiotropium via handihaler
Study NCT01239511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal
Study NCT01239511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: green tea polyphenols (STA-2)
Description: 2 capsules t.i.d., after meal
Study NCT00699894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant 40 mg
Description: aprepitant 40 mg PO 1-3 hours prior to surgery
Study NCT00699894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron 4 mg
Description: ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
Study NCT04100031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bandage contact lenses
Description: wear bandage contact lensesfor a week after cataract surgery.
Study NCT02374749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-assessment/self-management
Description: Nurse led-program of self-assessment/ self-management of spondyloarthritis
Study NCT02374749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comorbidities (detection/prevention)
Description: Standardized assessment of comorbidities by nurses
Study NCT04258423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Low dose Tacrolimus
Study NCT04258423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus
Study NCT02584946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
Study NCT02584946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
Study NCT03142386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Study NCT03142386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT00321789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: spouse-assisted intervention
Description: Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
Study NCT02511379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene Glycol 0.6% eye drops
Study NCT05256485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy,mindfulness based relapse prevention,twelve-step therapy
Description: In cognitive-behavioral therapy, participants learned that thoughts and emotions contribute to behavior, and responses to thoughts and emotions can be controlled.~in mindfulness-based relapse prevention, participants learned to focus on the present moment experience including craving with an attitude of acceptance and non-judging.~In twelve-step therapy, participants learned principles of acceptance, gratitude, forgiveness, tolerance, patience, humility, and honesty together with participation in different healthy ways to enrich life.
Study NCT02681198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
Study NCT02681198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
Study NCT02854046 — intervention group
Intervention type: OTHER
Intervention: Calcific Uremic Arteriolopathy
Study NCT03082690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoGel
Description: 1% IQP-0528 in gel formulation
Study NCT01259141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 0.4 Qd for 7days
Study NCT01259141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporins and azithromycin
Description: cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
Study NCT02507765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02507765 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02507765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE
Study NCT02153632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine HCl ER
Description: Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
Study NCT02153632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects are given an identical placebo tablet
Study NCT02352480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
Study NCT04960449 — intervention group
Intervention type: PROCEDURE
Intervention: shoulder arthroscopy
Description: Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
Study NCT03151629 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Drugs routinely administered for metastatic prostate cancer per local standard.
Study NCT03226002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq NT
Description: channeled video laryngoscope for nasotracheal intubation
Study NCT00604565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: soluble ferric pyrophosphate (SFP)
Description: Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)
Study NCT00604565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
Study NCT04254393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE) Program
Description: EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.
Study NCT04254393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
Study NCT02260934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1000mg intravenously (IV) at week 0 and week 2
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: * Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Week 0 and Week 2:~Solumedrol (100 mg) IV
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study NCT02260934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000mg intravenously (IV) at week 0 and week 2.
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: * Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Week 0 and Week 2: Solumedrol (100 mg) IV
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study NCT02260934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study NCT02260934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
Study NCT02304939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changeover
Study NCT02304939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: changeover
Study NCT02304939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of automatic infusion pump
Study NCT02304939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: datas collection
Study NCT02304939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: datas collection
Study NCT00928902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose IL-2
Description: low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
Study NCT00928902 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: melanoma vaccine
Description: six melanoma vaccines given over a 6-week period
Study NCT00152503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seletracetam (UCB44212)
Description: * Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration
Study NCT01862289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic of chronic hyperventilation syndrome
Description: Nijmegen questionnaire, Hyperventilation challenge and blood gases
Study NCT00768417 — intervention group
Intervention type: BEHAVIORAL
Intervention: 10 chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
Study NCT00768417 — intervention group
Intervention type: BEHAVIORAL
Intervention: 25 Chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.